Effect of diacerein as an add-on to metformin in patients with type 2 diabetes mellitus and inadequate glycemic control
ABSTRACT Objective To evaluate the effect of diacerein as an add-on to metformin in patients with type 2 diabetes mellitus (T2DM) and inadequate glycemic control. Materials and methods A randomized, double-blind, placebo-controlled clinical trial was carried out on 12 patients with T2DM and inadequate glycemic control [glycated hemoglobin A1c (A1C) ≥ 7%] with metformin as monotherapy (≥ 1500 mg per day) for at least the previous 90 days. Fasting and postprandial glucose were measured before and after the pharmacological intervention. A1C, lipid profile, creatinine and uric acid were also evaluated. After randomization, all patients continued with their dose of metformin. Six subjects received placebo and the other six volunteers took diacerein. Data were tested using the Wilcoxon signed-rank, Mann-Whitney U and chi-square tests. The Institutional Ethics Committee approved the study protocol. Results After 90 days of diacerein as an add-on to metformin, there was a significant decrease in fasting glucose (196 ± 79 vs. 149 ± 70 mg/dL, p < 0.05), postprandial glucose (262 ± 99 vs. 187 ± 70 mg/dlL, p < 0.05) and A1C (8.4 ± 2.0 vs. 6.7 ± 1.7 %, p < 0.05). Conclusions Diacerein as an add-on to metformin in patients with T2DM improved their glycemic control.
Main Authors: | , , , |
---|---|
Format: | Digital revista |
Language: | English |
Published: |
Sociedade Brasileira de Endocrinologia e Metabologia
2017
|
Online Access: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S2359-39972017000200188 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
oai:scielo:S2359-39972017000200188 |
---|---|
record_format |
ojs |
spelling |
oai:scielo:S2359-399720170002001882017-04-24Effect of diacerein as an add-on to metformin in patients with type 2 diabetes mellitus and inadequate glycemic controlVillar,Miriam Méndez-delMartínez-Abundis,EsperanzaPreciado-Márquez,Rafael O.González-Ortiz,Manuel Diacerein metformin glycemic control type 2 diabetes mellitus ABSTRACT Objective To evaluate the effect of diacerein as an add-on to metformin in patients with type 2 diabetes mellitus (T2DM) and inadequate glycemic control. Materials and methods A randomized, double-blind, placebo-controlled clinical trial was carried out on 12 patients with T2DM and inadequate glycemic control [glycated hemoglobin A1c (A1C) ≥ 7%] with metformin as monotherapy (≥ 1500 mg per day) for at least the previous 90 days. Fasting and postprandial glucose were measured before and after the pharmacological intervention. A1C, lipid profile, creatinine and uric acid were also evaluated. After randomization, all patients continued with their dose of metformin. Six subjects received placebo and the other six volunteers took diacerein. Data were tested using the Wilcoxon signed-rank, Mann-Whitney U and chi-square tests. The Institutional Ethics Committee approved the study protocol. Results After 90 days of diacerein as an add-on to metformin, there was a significant decrease in fasting glucose (196 ± 79 vs. 149 ± 70 mg/dL, p < 0.05), postprandial glucose (262 ± 99 vs. 187 ± 70 mg/dlL, p < 0.05) and A1C (8.4 ± 2.0 vs. 6.7 ± 1.7 %, p < 0.05). Conclusions Diacerein as an add-on to metformin in patients with T2DM improved their glycemic control.info:eu-repo/semantics/openAccessSociedade Brasileira de Endocrinologia e MetabologiaArchives of Endocrinology and Metabolism v.61 n.2 20172017-03-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S2359-39972017000200188en10.1590/2359-3997000000242 |
institution |
SCIELO |
collection |
OJS |
country |
Brasil |
countrycode |
BR |
component |
Revista |
access |
En linea |
databasecode |
rev-scielo-br |
tag |
revista |
region |
America del Sur |
libraryname |
SciELO |
language |
English |
format |
Digital |
author |
Villar,Miriam Méndez-del Martínez-Abundis,Esperanza Preciado-Márquez,Rafael O. González-Ortiz,Manuel |
spellingShingle |
Villar,Miriam Méndez-del Martínez-Abundis,Esperanza Preciado-Márquez,Rafael O. González-Ortiz,Manuel Effect of diacerein as an add-on to metformin in patients with type 2 diabetes mellitus and inadequate glycemic control |
author_facet |
Villar,Miriam Méndez-del Martínez-Abundis,Esperanza Preciado-Márquez,Rafael O. González-Ortiz,Manuel |
author_sort |
Villar,Miriam Méndez-del |
title |
Effect of diacerein as an add-on to metformin in patients with type 2 diabetes mellitus and inadequate glycemic control |
title_short |
Effect of diacerein as an add-on to metformin in patients with type 2 diabetes mellitus and inadequate glycemic control |
title_full |
Effect of diacerein as an add-on to metformin in patients with type 2 diabetes mellitus and inadequate glycemic control |
title_fullStr |
Effect of diacerein as an add-on to metformin in patients with type 2 diabetes mellitus and inadequate glycemic control |
title_full_unstemmed |
Effect of diacerein as an add-on to metformin in patients with type 2 diabetes mellitus and inadequate glycemic control |
title_sort |
effect of diacerein as an add-on to metformin in patients with type 2 diabetes mellitus and inadequate glycemic control |
description |
ABSTRACT Objective To evaluate the effect of diacerein as an add-on to metformin in patients with type 2 diabetes mellitus (T2DM) and inadequate glycemic control. Materials and methods A randomized, double-blind, placebo-controlled clinical trial was carried out on 12 patients with T2DM and inadequate glycemic control [glycated hemoglobin A1c (A1C) ≥ 7%] with metformin as monotherapy (≥ 1500 mg per day) for at least the previous 90 days. Fasting and postprandial glucose were measured before and after the pharmacological intervention. A1C, lipid profile, creatinine and uric acid were also evaluated. After randomization, all patients continued with their dose of metformin. Six subjects received placebo and the other six volunteers took diacerein. Data were tested using the Wilcoxon signed-rank, Mann-Whitney U and chi-square tests. The Institutional Ethics Committee approved the study protocol. Results After 90 days of diacerein as an add-on to metformin, there was a significant decrease in fasting glucose (196 ± 79 vs. 149 ± 70 mg/dL, p < 0.05), postprandial glucose (262 ± 99 vs. 187 ± 70 mg/dlL, p < 0.05) and A1C (8.4 ± 2.0 vs. 6.7 ± 1.7 %, p < 0.05). Conclusions Diacerein as an add-on to metformin in patients with T2DM improved their glycemic control. |
publisher |
Sociedade Brasileira de Endocrinologia e Metabologia |
publishDate |
2017 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S2359-39972017000200188 |
work_keys_str_mv |
AT villarmiriammendezdel effectofdiacereinasanaddontometformininpatientswithtype2diabetesmellitusandinadequateglycemiccontrol AT martinezabundisesperanza effectofdiacereinasanaddontometformininpatientswithtype2diabetesmellitusandinadequateglycemiccontrol AT preciadomarquezrafaelo effectofdiacereinasanaddontometformininpatientswithtype2diabetesmellitusandinadequateglycemiccontrol AT gonzalezortizmanuel effectofdiacereinasanaddontometformininpatientswithtype2diabetesmellitusandinadequateglycemiccontrol |
_version_ |
1756441375970164736 |